Mettler-Toledo International Inc. (MTD) exhibits 59.4% gross margins and 30.4% return on invested capital within Health Care (Biotechnology: Laboratory Analytical Instruments), balanced against a 31.7x enterprise multiple and 4.8% implied options volatility.
Sustained 59.4% gross profitability converts into 26.3% operating margin and 30.4% ROIC, outpacing sector cost of capital.
ROIC: 30.4% // GM: 59.4%YoY revenue trajectory of +4.0% paired with 2.46% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +4.0% // FCF YLD: 2.46%Altman Z-Score of 11.09 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 11.09 // F-SCORE: 8/9Trading at 39.6x trailing P/E (36.8x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 39.6x // EV/EBITDA: 31.7xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $1,674.81 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Laboratory Analytical Instruments require continuous execution to defend 21.6% net margins.
NET MARGIN: 21.6% // D/E: 0.85x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for MTD & activate live FRED threshold breach alerts.